AgingResearch.NewsJoin free

Radella Pharmaceuticals

Company

Radella Pharmaceuticals develops one asset, in phase 1 (MD-18 in obesity). Mostly peptide acting on Insulin/IGF-1 signalling and PTPN1.

1
Asset
Furthest stage
Phase 1
0
Trials
1
Signal

Pipeline

1

  • MD-18

    Disrupts Nck1 binding to specifically inhibit PTP-1B activity and improve insulin sensitivity.

    Phase 1, Peptide, Insulin/IGF-1 signalling, PTPN1, obesity, type 2 diabetes

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Signals2
  • Similar companies6

Papers

Intelligence